Dynamics of survival in patients with ovarian cancer III-IV degree


  • A.I. Rybin
  • V.S. Svintsitsky
Keywords: ovarian cancer, survival, treatment.

Abstract

The aim of the study was assessment of survival dynamics of ovarian cancer. The survey was conducted on the basis of OOD (c. Odessa) for 2010 - 2015 were examined 350 patients with ovarian adenocarcinoma of III-IV stage, which was carried with cytoreduction surgery. The average age of patients was 55,3 ± 3,9 years. The sample was dominated by patients with stage IIIC - on average there were 64.9% of the total sample. It is shown that the introduction of integrated circuits based pathogenesis of drug therapy with considering the platinum-resistance  can significantly prolong the survival of patients with ovarian cancer. Pathogenetic therapy based on pharmacogenetic peculiarities can significantly improve treatment outcomes (up to 33,1 ± 1,4 months in patients likely to platinum resistance and 36,8 ± 1,9 months in platinum sensitive cases). If probable platynorezystentnosti advisable due to the standard first-line therapy drug use dyzrehulyatsiynyh adjustment disorders (donors of nitric oxide, detoxicant, antyurykemichni means). With predictable platinum sensitivity the standard first-line treatment can be supplemented with medications improving tolerance to, but the use of the medications for correction of disregulatory disorders is inappropriate.

References

1. Ivchenko, A. L. (2015). Rak yaichnikov: sovremennye aspekty diagnostiki. Kharkivska khirurhichna shkola, 4, 147–151. [in Russian].

2. MOZ Ukrainy № 554 vid 17.09.2007 «Pro zatverdzhennia protokoliv nadannia medychnoi dopomohy za spetsialnistiu «onkolohiia». Vziato z http://www.moz.gov.ua/ua/portal/dn_20070917_554.html. [in Ukrainian].

3. Natsionalnyi kantser-reiestr. Vziato z http://unci.org.ua/spetsialistam/nacionalnij-kancer-reyestr. [in Ukrainian].

4. Rybin, A. I., Lysenko, M. A. & Rysina, A. (2014). Osoblyvosti systemy sanoheneza u khvorykh na rak yaiechnykiv, shcho rezystentni do khimioterapii preparatamy platyny. Zbirnyk naukovykh prats Asotsiatsii akusheriv-hinekolohiv Ukrainy, 1–2, 251–254. [in Ukrainian].

5. Tyulyandina, A. S. (2013). Nastoyashee i budushee targetnoj terapii v pervoj linii lecheniya raka yaichnikov. Farmateka, 8(261), 39–42. [in Russian].

6. Halafyan, A. A. (2008). Statistica 6. Statisticheskij analiz dannyh. Moskva: OOO «Binom-Press». [in Russian].

7. Chernobaj, A. V. (2013). Rak yaichnika: patogenez, diagnostika, sovremennye aspekty lecheniya. Vestnik problem biologii i mediciny, 1(2). 033–038. [in Russian].

8. Bray, F., Loos, A. H. & Tognazzo, S. (2005). Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953–2000. Int. J. Cancer, 113 (6), 977–90.

9. Sopik, V., Iqbal, J., Rosen, B. & Narod, S. A. (2015). Why have ovarian cancer mortality rates declined? (Part I.). Incidence. Gynecol Oncol., 138 (3), 741–9.

10. Weiderpass, E. & Botteri, E. (2016). Ovarian cancer mortality trends: which factors are involved? Ann. Oncol., 27 (11), 1977–1978.
Published
2017-09-29
How to Cite
Rybin, A., & Svintsitsky, V. (2017). Dynamics of survival in patients with ovarian cancer III-IV degree. Reports of Vinnytsia National Medical University, 21(1(2), 294-297. Retrieved from https://reports-vnmedical.com.ua/index.php/journal/article/view/134